Somatic mutation of DNAH genes implicated higher chemotherapy response rate in gastric adenocarcinoma patients.

ABSTRACT:

Background

The dynein axonemal heavy chain (DNAH) family of genes encode the dynein axonemal heavy chain, which is involved in cell motility. Genomic variations of DNAH family members have been frequently reported in diverse kinds of malignant tumors. In this study, we analyzed the genomic database to evaluate the mutation status of DNAH genes in gastric adenocarcinoma and further identified the significance of mutant DNAH genes as effective molecular biomarkers for predicting chemotherapy response in gastric cancer patients.

Methods

We analyzed the clinical and genomic data of gastric cancer patients published in The Cancer Genome Atlas (TCGA) project. Data on chemotherapy response, overall survival (OS) and chemotherapy-free survival were retrieved. Then, we verified the r

SUBMITTER: Zhu C 

PROVIDER: S-EPMC6448266 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature